Tags

Type your tag names separated by a space and hit enter

A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients.
Int J Clin Pract. 2006 Aug; 60(8):922-32.IJ

Abstract

This study evaluates the cost-effectiveness of Omacor treatment as a standard prevention measure post-MI in the UK. A cost-effectiveness model was developed based on the GISSI-P trial, combining a survival and a Markov model, over a lifetime period. The base case results for Omacor, at 4 years and over a lifetime, respectively, were: cost [corrected] per QALY gained: pound15,189 and 3,723; [corrected] cost per life years gained (LYG): pound12,011 and pound2,812 [corrected] The cost per death avoided at 4 years was pound31,786. Deterministic and probabilistic sensitivity analyses did not change the base case results substantially. The use of Omacor as a standard post-MI prevention treatment seems warranted in the UK, both on the basis of its efficacy, which is in addition to other prophylactic treatments as evidenced by the results of the GISSI-P trial, and on cost-effectiveness grounds - both at 4 years and over a lifetime's time-horizon, using the current cost-effectiveness thresholds.

Authors+Show Affiliations

i3 Innovus, Uxbridge, Middlesex, UK. squilici@innovus.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16893435

Citation

Quilici, S, et al. "A Cost-effectiveness Analysis of N-3 PUFA (Omacor) Treatment in post-MI Patients." International Journal of Clinical Practice, vol. 60, no. 8, 2006, pp. 922-32.
Quilici S, Martin M, McGuire A, et al. A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. Int J Clin Pract. 2006;60(8):922-32.
Quilici, S., Martin, M., McGuire, A., & Zoellner, Y. (2006). A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. International Journal of Clinical Practice, 60(8), 922-32.
Quilici S, et al. A Cost-effectiveness Analysis of N-3 PUFA (Omacor) Treatment in post-MI Patients. Int J Clin Pract. 2006;60(8):922-32. PubMed PMID: 16893435.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. AU - Quilici,S, AU - Martin,M, AU - McGuire,A, AU - Zoellner,Y, PY - 2006/8/9/pubmed PY - 2007/4/7/medline PY - 2006/8/9/entrez SP - 922 EP - 32 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 60 IS - 8 N2 - This study evaluates the cost-effectiveness of Omacor treatment as a standard prevention measure post-MI in the UK. A cost-effectiveness model was developed based on the GISSI-P trial, combining a survival and a Markov model, over a lifetime period. The base case results for Omacor, at 4 years and over a lifetime, respectively, were: cost [corrected] per QALY gained: pound15,189 and 3,723; [corrected] cost per life years gained (LYG): pound12,011 and pound2,812 [corrected] The cost per death avoided at 4 years was pound31,786. Deterministic and probabilistic sensitivity analyses did not change the base case results substantially. The use of Omacor as a standard post-MI prevention treatment seems warranted in the UK, both on the basis of its efficacy, which is in addition to other prophylactic treatments as evidenced by the results of the GISSI-P trial, and on cost-effectiveness grounds - both at 4 years and over a lifetime's time-horizon, using the current cost-effectiveness thresholds. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/16893435/A_cost_effectiveness_analysis_of_n_3_PUFA__Omacor__treatment_in_post_MI_patients_ L2 - https://doi.org/10.1111/j.1742-1241.2006.01009.x DB - PRIME DP - Unbound Medicine ER -